Draft:RMC-9805

RMC-9805
Clinical data
Drug class	Antineoplastic agents
Identifiers
	IUPAC name (2S)-2-Cyclopentyl-2-[(5S)-7-{[(2R,3R)-3-cyclopropyl-1-methyl-2-aziridinyl]carbonyl}-2,7-diazaspiro[4.4]non-2-yl]-N-[(6S,8S,14S)-21-{5-(4-cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl }-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetraazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(25),20,23,26-tetraen-8-yl]acetamide;
CAS Number	2922732-54-3;
PubChem CID	168201327;
ChemSpider	128942583;
Chemical and physical data
Formula	C63H88F3N11O7
Molar mass	1168.462 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N1CCC[C@@H]2N1)[C@H](C[C@@H](C3)OCCN3C4=CC5=C(N(CC(F)(F)F)[C@]([C@]6=C([C@H](C)OC)N=CC(N7CCN(C8CC8)CC7)=C6)=C5CC(C)(C)COC2=O)C=C4)NC([C@@H](N9C[C@]%10(CN(C([C@@H]%11N(C)[C@@H]%11C%12CC%12)=O)CC%10)CC9)C%13CCCC%13)=O;
	InChI InChI=InChI=1S/C63H88F3N11O7/c1-39(82-5)52-47(30-44(33-67-52)72-25-23-71(24-26-72)42-14-15-42)55-48-32-61(2,3)38-84-60(81)49-11-8-20-77(69-49)58(79)50(31-45-34-73(27-28-83-45)43-16-17-51(46(48)29-43)76(55)37-63(64,65)66)68-57(78)54(40-9-6-7-10-40)74-21-18-62(35-74)19-22-75(36-62)59(80)56-53(70(56)4)41-12-13-41/h16-17,29-30,33,39-42,45,49-50,53-54,56,69H,6-15,18-28,31-32,34-38H2,1-5H3,(H,68,78)/t39?,45-,49-,50-,53+,54-,56+,62-,70?/m0/s1; Key:VKNNQJWNUPSOEK-QFVODIEJSA-N;

Submission declined on 2 December 2024 by Chaotic Enby (talk).

This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:

in-depth (not just passing mentions about the subject)
reliable
secondary
independent of the subject

Make sure you add references that meet these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.

If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.

Where to get help

If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.

How to improve a draft

Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia.
Help:Wikitext – how to use the markup
Help:Referencing for beginners – how to include references
Wikipedia:Article development – how to develop your article
Wikipedia:Writing better articles – how to improve your article
Wikipedia:Verifiability – make sure your article includes reliable third-party sources

You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article.

Improving your odds of a speedy review

To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Add tags to your draft

Editor resources

Easy tools: Citation bot (help) | Advanced: Fix bare URLs

Declined by Chaotic Enby 19 hours ago. Last edited by DMacks 2 seconds ago. Reviewer: Inform author.

Resubmit

Please note that if the issues are not fixed, the draft will be declined again.

Comment: Close to being notable, but I'm afraid it's just missing a bit of sourcing to go over the line. Adinsight appears to be a database information profile, so I'm not sure if it helps that much, while Zeissig et al. is good but doesn't go too much in-depth. De Jesus et al. is certainly a very solid source, and adding another source like this one would certainly be enough for notability. I'm not counting the ongoing clinical trial as a source counting for notability, because it is, well, ongoing, although independent reporting on the clinical trial would definitely count too! Chaotic Enby (talk · contribs) 10:44, 2 December 2024 (UTC)

RMC-9805 is an investigational drug that targets the G12D mutation in KRAS dependent cancers.^[1]^[2]^[3] It is currently in a phase 1 clinical trial for the treatment of solid tumors.^[4]

References

^ "RMC-9805". AdisInsight. Springer Nature Switzerland AG.
^ Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD (November 2023). "Next batter up! Targeting cancers with KRAS-G12D mutations". Trends in Cancer. 9 (11): 955–967. doi:10.1016/j.trecan.2023.07.010. PMID 37591766.
^ de Jesus VH, Mathias-Machado MC, de Farias JP, Aruquipa MP, Jácome AA, Peixoto RD (October 2023). "Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure". Cancers. 15 (20): 5015. doi:10.3390/cancers15205015. PMC 10605759. PMID 37894382.
^ Clinical trial number NCT06040541 for "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Category:Antineoplastic drugs

[1] "RMC-9805". AdisInsight. Springer Nature Switzerland AG.

[Zeissig_2023-2] Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD (November 2023). "Next batter up! Targeting cancers with KRAS-G12D mutations". Trends in Cancer. 9 (11): 955–967. doi:10.1016/j.trecan.2023.07.010. PMID 37591766.

[“deJesus_2023"-3] Jesus VH, Mathias-Machado MC, de Farias JP, Aruquipa MP, Jácome AA, Peixoto RD (October 2023). "Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure". Cancers. 15 (20): 5015. doi:10.3390/cancers15205015. PMC 10605759. PMID 37894382.

[4] Clinical trial number NCT06040541 for "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors" at ClinicalTrials.gov

[1]

[2]

[3]

[4]

See also

References